Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00235820 | Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis | PHASE3 | COMPLETED | 271 | — | — | Jul 1, 2005 | - | Jul 17, 2008 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| C | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| adalimumab | DRUG | 40 mg every other week following an 80 mg dose |
| MTX | DRUG | MTX 7.5 to 25 mg once weekly |
| placebo adalimumab, placebo MTX | DRUG | placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX) |
Inclusion Criteria: * Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history who has had a diagnosis of psoriasis for at least 12 months and stable moderate to severe chronic plaque psoriasis * Subject is a candidate for systemic therapy or pho...